Maria Masnata

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Implementation of a neuromuscular clinical trial network: a rare disease model for enhancing clinical trial readiness, capacity, and access in Canada.

Implementation of a neuromuscular clinical trial network: a rare disease model for enhancing clinical trial readiness, capacity, and access in Canada.

Journal: Orphanet journal of rare diseases

Published: March 11, 2026

Strengthening clinical capacity in spinal muscular atrophy: Developing and implementing training on clinical outcome assessments.

Strengthening clinical capacity in spinal muscular atrophy: Developing and implementing training on clinical outcome assessments.

Journal: Journal of neuromuscular diseases

Published: January 21, 2026

Cell-free miRNAs are pharmacodynamic biomarkers for enhanced DICER activity by enoxacin in human patients with ALS.

Cell-free miRNAs are pharmacodynamic biomarkers for enhanced DICER activity by enoxacin in human patients with ALS.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 06, 2025

Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severity.

Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severity.

Journal: Journal of neurology

Published: December 23, 2024

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.

Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 17, 2021

Correction: Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology.

Correction: Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology.

Journal: Molecular psychiatry

Published: July 26, 2020

Targeting Tau to Treat Clinical Features of Huntington's Disease.

Targeting Tau to Treat Clinical Features of Huntington's Disease.

Journal: Frontiers in neurology

Published: July 06, 2020

Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology.

Shedding a new light on Huntington's disease: how blood can both propagate and ameliorate disease pathology.

Journal: Molecular psychiatry

Published: January 07, 2020

Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates.

Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates.

Journal: Neurobiology of disease

Published: December 09, 2019

Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms.

Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms.

Journal: Acta neuropathologica

Published: December 18, 2018

The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications.

The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications.

Journal: Frontiers in neuroscience

Published: September 19, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026